Hollak CE - Search Results

1

Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain.

Rombach SM, Smid BE, Bouwman MG, Linthorst GE, Dijkgraaf MG, Hollak CE. Rombach SM, et al. Among authors: hollak ce. Orphanet J Rare Dis. 2013 Mar 25;8:47. doi: 10.1186/1750-1172-8-47. Orphanet J Rare Dis. 2013. PMID: 23531228 Free PMC article.

2

[Fabry's disease; towards a treatment].

Linthorst GE, Hollak CE, Bosman DK, Heymans HS, Aerts JM. Linthorst GE, et al. Among authors: hollak ce. Ned Tijdschr Geneeskd. 2000 Dec 9;144(50):2391-5. Ned Tijdschr Geneeskd. 2000. PMID: 11145093 Review. Dutch.

3

Enzyme replacement in Anderson-Fabry disease.

Bengtsson BA, Johansson JO, Hollak C, Linthorst G, FeldtRasmussen U. Bengtsson BA, et al. Lancet. 2003 Jan 25;361(9354):352. doi: 10.1016/S0140-6736(03)12357-4. Lancet. 2003. PMID: 12559898 No abstract available.

4

[European ordinance on orphan drugs: changes and threats].

Linthorst GE, Hollak CE. Linthorst GE, et al. Among authors: hollak ce. Ned Tijdschr Geneeskd. 2003 Jan 25;147(4):143-5. Ned Tijdschr Geneeskd. 2003. PMID: 12635543 Dutch.

5

alpha-Galactosidase A deficiency in Dutch patients on dialysis: a critical appraisal of screening for Fabry disease.

Linthorst GE, Hollak CE, Korevaar JC, Van Manen JG, Aerts JM, Boeschoten EW. Linthorst GE, et al. Among authors: hollak ce. Nephrol Dial Transplant. 2003 Aug;18(8):1581-4. doi: 10.1093/ndt/gfg194. Nephrol Dial Transplant. 2003. PMID: 12897098

6

Blood group does not correlate with disease severity in patients with Fabry disease (alpha-galactosidase A deficiency).

Linthorst GE, Folman CC, Aerts JM, Hollak CE. Linthorst GE, et al. Among authors: hollak ce. Blood Cells Mol Dis. 2003 Nov-Dec;31(3):324-6. doi: 10.1016/s1079-9796(03)00163-3. Blood Cells Mol Dis. 2003. PMID: 14636646

7

Chloroquine-induced phospholipidosis of the kidney mimicking Fabry's disease.

Linthorst GE, Hollak CE. Linthorst GE, et al. Among authors: hollak ce. Hum Pathol. 2003 Dec;34(12):1358; author reply 1358-9. doi: 10.1016/s0046-8177(03)00396-4. Hum Pathol. 2003. PMID: 14691926 No abstract available.

8

Misdiagnosis of Fabry disease: importance of biochemical confirmation of clinical or pathological suspicion.

Linthorst GE, De Rie MA, Tjiam KH, Aerts JM, Dingemans KP, Hollak CE. Linthorst GE, et al. Among authors: hollak ce. Br J Dermatol. 2004 Mar;150(3):575-7. doi: 10.1046/j.1365-2133.2004.05813.x. Br J Dermatol. 2004. PMID: 15030345

9

Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta.

Linthorst GE, Hollak CE, Donker-Koopman WE, Strijland A, Aerts JM. Linthorst GE, et al. Among authors: hollak ce. Kidney Int. 2004 Oct;66(4):1589-95. doi: 10.1111/j.1523-1755.2004.00924.x. Kidney Int. 2004. PMID: 15458455 Free article. Clinical Trial.

10

Screening for Fabry disease using whole blood spots fails to identify one-third of female carriers.

Linthorst GE, Vedder AC, Aerts JM, Hollak CE. Linthorst GE, et al. Among authors: hollak ce. Clin Chim Acta. 2005 Mar;353(1-2):201-3. doi: 10.1016/j.cccn.2004.10.019. Clin Chim Acta. 2005. PMID: 15698608

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

317 results

Search Page